Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study-Reference-Cited by-同舟云学术

Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study

Published:2019-02-08 Issue:2 Volume:25 Page:219-225
ISSN:1075-122X
Container-title:The Breast Journal
language:en
Short-container-title:Breast J

Author:

Manso Luis¹^ORCID,Moreno Antón Fernando²,Izarzugaza Perón Yann³,Delgado Mingorance Juan I.⁴,Borrega García Pablo⁵,Echarri González María J.⁶,Martínez-Jañez Noelia⁷,López-González Ana⁸,Olier Garate Clara⁹,Ballesteros García Anabel¹⁰,Chacón López-Muñíz Ignacio¹¹,Ciruelos Gil Eva¹,García-Sáenz Jose Angel²,Paz-Ares Luis¹

Affiliation:

1. Medical Oncology Department; Hospital 12 De Octubre; Madrid Spain

2. Medical Oncology Department; Hospital Clínico San Carlos; Madrid Spain

3. Medical Oncology Department; Hospital “Fundacion Jiménez Díaz”; Madrid Spain

4. Medical Oncology Department; Hospital Infanta Cristina; Badajoz Spain

5. Medical Oncology Department; Hospital San Pedro de Alcántara; Cáceres Spain

6. Medical Oncology Department; Hospital Severo Ochoa; Leganés Spain

7. Medical Oncology Department; Hospital Ramón y Cajal; Madrid Spain

8. Medical Oncology Department; Hospital de León; León Spain

9. Medical Oncology Department; Hospital Fundación Alcorcón; Alcorcón Spain

10. Medical Oncology Department; Hospital La Princesa; Madrid Spain

11. Medical Oncology Department; Hospital Virgen de la Salud; Toledo Spain

Funder

Eisai Farmacéutica SA

Publisher

Hindawi Limited

Subject

Oncology,Surgery,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/tbj.13199/fullpdf

Reference32 articles.

1. Cancer Stat Facts: Female Breast Cancer. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program 2017 https://seer.cancer.gov/statfacts/html/breast.html

2. Cancer incidence in Spain, 2015;Galceran;Clin Transl Oncol,2017

3. Taxanes in the first-line chemotherapy of metastatic breast cancer: review;Friedrich;Eur J Gynaecol Oncol,2004

4. Taxane-containing regimens for metastatic breast cancer;Ghersi;Cochrane Database Syst Rev,2015

5. How to maximize the efficacy of taxanes in breast cancer;Tubiana-Hulin;Cancer Treat Rev,2005

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eribulin in Metastatic Breast Cancer: Actual Clinical Practice;Creative surgery and oncology;2023-04-05

2. Triple negative breast cancer: second and successive lines of treatment;Revisiones en Cáncer;2023

3. Effectiveness of combination with eribulin in third line of chemotherapy for triple negative breast cancer (case report);Medical alphabet;2021-12-06

4. Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors;Cancer Medicine;2021-11-28

5. Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story;Expert Opinion on Drug Safety;2021-10-13